Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
ENROLLING BY INVITATION
NCT05688579
PHASE4

Effect of MRA on Cardiovascular Disease in Patients With Hypertension and Hyperaldosteronemia

Sponsor: Nanfang Li

View on ClinicalTrials.gov

Summary

Elevated aldosterone causes moderate to severe increase in blood pressure, and leads to various target organ damage including cardiovascular ones. Aldosterone has been considered one of the important risk factors for cardiovascular and cerebrovascular diseases. Currently, the use of mineralocorticoid receptor antagonists(MRA) has been proven to reduce blood pressure levels, but long-term prognostic data are lacking in hypertensive patients. Therefore, the purpose of this clinical trial is to assess the effect of MRA on cardiovascular disease in patients with Hypertension and Hyperaldosteronemia.

Official title: Effect of Mineralcorticoid Recept Antagonist on Cardiovascular Disease in Patients With Hypertension and Hyperaldosteronemia:A Multicenter Randomized Controlled Study

Key Details

Gender

All

Age Range

30 Years - 75 Years

Study Type

INTERVENTIONAL

Enrollment

8000

Start Date

2023-04-16

Completion Date

2026-12-31

Last Updated

2023-04-18

Healthy Volunteers

No

Interventions

DRUG

Mineralocorticoid Receptor Antagonists(MRAs)

Participants will be treated with mineralocorticoid receptor antagonists(MRAs) in addition to the original antihypertensive drugs for 48 months.

OTHER

Blank control

Participants will be treated with the original antihypertensive drugs for 48 months.

Locations (1)

Hypertension Center of People's Hospital of Xinjiang Uygur Autonomous Region

Ürümqi, Xinjiang, China